TY - JOUR
T1 - Characterisation of the immune-related transcriptome in resected biliary tract cancers
AU - Ghidini, Michele
AU - Ghidini, Michele
AU - Ghidini, Michele
AU - Cascione, Luciano
AU - Carotenuto, Pietro
AU - Lampis, Andrea
AU - Trevisani, Francesco
AU - Trevisani, Francesco
AU - Previdi, Maria Chiara
AU - Hahne, Jens C.
AU - Said-Huntingford, Ian
AU - Raj, Maya
AU - Zerbi, Alessandro
AU - Mescoli, Claudia
AU - Cillo, Umberto
AU - Rugge, Massimo
AU - Roncalli, Massimo
AU - Torzilli, Guido
AU - Rimassa, Lorenza
AU - Santoro, Armando
AU - Valeri, Nicola
AU - Valeri, Nicola
AU - Fassan, Matteo
AU - Braconi, Chiara
AU - Braconi, Chiara
PY - 2017/11/1
Y1 - 2017/11/1
N2 - © 2017 The Author(s) Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling Panel was used to assess the expression of 770 immune-related transcripts in the tumour tissues (TTs) and matched adjacent tissues (ATs) of resected BTCs. Cox regression analysis and Kaplan–Meier methods were used to correlate findings with relapse-free survival (RFS). The first analysis in the TT and AT of an exploratory set (n = 22) showed deregulation of 39 transcripts associated with T-cell activation. Risk of recurrence was associated with a greater number of genes deregulated in AT in comparison to TT. Analysis in the whole set (n = 53) showed a correlation between AT cytotoxic T-lymphocyte antigen-4 (CTLA4) expression and RFS, which maintained statistical significance at multivariate analysis. CTLA4 expression correlated with forkhead box P3 (FOXP3) expression, suggesting enrichment in T regulatory cells. CTLA4 is known to act by binding to the cluster of differentiation 80 (CD80). No association was seen between AT CD80 expression and RFS. However, CD80 expression differentiated prognosis in patients who received adjuvant chemotherapy. We showed that the immunomodulatory transcriptome is deregulated in resected BTCs. Our study includes a small number of patients and does not enable to draw definitive conclusions; however, it provides useful insights into potential transcripts that may deserve further investigation in larger cohorts of patients. Transcript Profiling Nanostring data have been submitted to GEO repository: GSE906 98 and GSE90699.
AB - © 2017 The Author(s) Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling Panel was used to assess the expression of 770 immune-related transcripts in the tumour tissues (TTs) and matched adjacent tissues (ATs) of resected BTCs. Cox regression analysis and Kaplan–Meier methods were used to correlate findings with relapse-free survival (RFS). The first analysis in the TT and AT of an exploratory set (n = 22) showed deregulation of 39 transcripts associated with T-cell activation. Risk of recurrence was associated with a greater number of genes deregulated in AT in comparison to TT. Analysis in the whole set (n = 53) showed a correlation between AT cytotoxic T-lymphocyte antigen-4 (CTLA4) expression and RFS, which maintained statistical significance at multivariate analysis. CTLA4 expression correlated with forkhead box P3 (FOXP3) expression, suggesting enrichment in T regulatory cells. CTLA4 is known to act by binding to the cluster of differentiation 80 (CD80). No association was seen between AT CD80 expression and RFS. However, CD80 expression differentiated prognosis in patients who received adjuvant chemotherapy. We showed that the immunomodulatory transcriptome is deregulated in resected BTCs. Our study includes a small number of patients and does not enable to draw definitive conclusions; however, it provides useful insights into potential transcripts that may deserve further investigation in larger cohorts of patients. Transcript Profiling Nanostring data have been submitted to GEO repository: GSE906 98 and GSE90699.
KW - Adjuvant
KW - CD80
KW - Cholangiocarcinoma
KW - CTLA4
KW - Treg
UR - http://www.scopus.com/inward/record.url?scp=85030567436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030567436&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2017.09.005
DO - 10.1016/j.ejca.2017.09.005
M3 - Article
C2 - 28988016
AN - SCOPUS:85030567436
VL - 86
SP - 158
EP - 165
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -